Finally, a new drug slows Alzheimer’s, but is it worth the price for modest benefit?

The Alzheimer’s disease medication Leqembi has been approved by the FDA for patients in early stages of the disease. It’s not a cure but slowed progression early on by several months. (Provided)

The federal Food and Drug Administration has approved a new drug for Alzheimer’s disease that is the first to show clear evidence that it can slow the mind-robbing disease. 

The drug — lecanemab, which will be sold under the brand name Leqembi — can slow the progression of Alzheimer’s in its early stages by several months.